Skip to content
by Legal Desire
28 December 2023

Latham & Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio

Advising firms

Deal team

22 lawyers named
LawyerFirmSeniorityPracticeOffice
Leah Sauter Lead Latham & Watkins LLP Partner corporate Not stated
Peter Handrinos Lead Latham & Watkins LLP Partner corporate Not stated
Elizabeth Slawsby Latham & Watkins LLP Associate corporate Not stated
Junhan Zhang Latham & Watkins LLP Associate corporate Not stated
Katharine Moir Latham & Watkins LLP Partner tax Not stated
Rasha Suleiman Latham & Watkins LLP Associate tax Not stated
Derek Gumm Latham & Watkins LLP Associate tax Not stated
Matt Conway Latham & Watkins LLP Partner benefits Not stated
Ashlie Lawton Latham & Watkins LLP Associate benefits Not stated
Dane Rebkowec Latham & Watkins LLP Associate benefits Not stated
Bryce Williamson Latham & Watkins LLP Associate benefits Not stated
Colleen Smith Latham & Watkins LLP Partner litigation Not stated
Steven Chinowsky Latham & Watkins LLP Partner intellectual property Not stated
Robert Yeh Latham & Watkins LLP Associate intellectual property Not stated
Kristina Funahashi Latham & Watkins LLP Associate intellectual property Not stated
Elisabeth Martin Latham & Watkins LLP Partner capital markets Not stated
Nicholas Reist Latham & Watkins LLP Associate capital markets Not stated
Ashley Dunn Latham & Watkins LLP Associate capital markets Not stated
Jenna Cooper Latham & Watkins LLP Partner public company representation Not stated
Nicole McNeil Latham & Watkins LLP Counsel public company representation Not stated
Hanna Downing Latham & Watkins LLP Associate public company representation Not stated
Patrick English Latham & Watkins LLP Counsel antitrust Not stated

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
Homology Medicines, Inc.Sell-side
Counterparties
Q32 Bio Inc. (Buy-side)